loading page

Shortening the Biologics Clinical Timeline with a Novel Method for Generating Stable, High Producing Cell Pools and Clones
  • +8
  • Chad A. Hall,
  • Rachel H. Kravitz,
  • Karl F. Johnson,
  • Nicholas A. Sanek,
  • Payel Maiti,
  • Keith R. Ziemba,
  • Jia Liu,
  • Dmitri O. Andreev,
  • Victoria L. Chrostowski,
  • Ian J. Collins,
  • Gregory Bleck
Chad A. Hall
Catalent Pharma Solutions
Author Profile
Rachel H. Kravitz
Catalent Pharma Solutions
Author Profile
Karl F. Johnson
Catalent Pharma Solutions
Author Profile
Nicholas A. Sanek
Catalent Pharma Solutions
Author Profile
Payel Maiti
Catalent Pharma Solutions
Author Profile
Keith R. Ziemba
Catalent Pharma Solutions
Author Profile
Jia Liu
Catalent Pharma Solutions
Author Profile
Dmitri O. Andreev
Catalent Pharma Solutions
Author Profile
Victoria L. Chrostowski
Catalent Pharma Solutions
Author Profile
Ian J. Collins
Catalent Pharma Solutions
Author Profile
Gregory Bleck
Catalent Pharma Solutions

Corresponding Author:[email protected]

Author Profile

Abstract

Reducing drug development timelines is an industry-wide goal to bring medicines to patients in need more quickly. This was exemplified in the COVID-19 pandemic where reducing development timelines had a direct impact on the number of lives lost to the disease. The use of drug substance produced using cell pools, as opposed to clones, has the potential to shorten development timelines. Toward this goal, we have developed a novel technology, GPEx® Lightning, that allows for rapid, reproducible, targeted recombination of transgenes into more than 200 Dock sites in the CHO genome. This allows for rapid production of high expressing stable cell pools and clones that reach titers of 4 to 12 g/L in generic fed-batch production. These pools and clones are highly stable in both titer and glycosylation, showing strong similarity in glycosylation profiles.
14 Dec 2022Submitted to Biotechnology and Bioengineering
15 Dec 2022Review(s) Completed, Editorial Evaluation Pending
15 Dec 2022Submission Checks Completed
15 Dec 2022Assigned to Editor
18 Dec 2022Reviewer(s) Assigned
19 Dec 2022Editorial Decision: Accept